Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug for patients with advanced solid tumors. It is the first time this drug is being tested in humans.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a specific type of cancer and benefited from previous immunotherapy.My cancer is advanced or has spread, and standard treatments have failed or aren't suitable.I have not had an infection needing treatment in the last 4 weeks.I have a serious lung condition.I have an autoimmune disease treated with strong medication in the last 2 years.I have a history of serious heart problems.I have melanoma that can't be removed by surgery and it got worse after treatment including an anti-PD-1.I have been treated with IL-2 therapy before.I have kidney cancer that worsened after treatment with specific immune and targeted therapies.My organs are working well.I have a BRAF V600 mutation and have been treated with targeted therapy.I am fully active or can carry out light work.I agree to give fresh tumor samples before and after starting the study treatment.I have been diagnosed with an immune system disorder.
- Group 1: Phase 1 XTX202 Dose Escalation and Pharmacodynamics Expansion
- Group 2: Phase 2 XTX202 Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still openings available for individuals to join this clinical trial?
"According to the info on clinicaltrials.gov, this research effort is still recruiting participants. It was originally posted 18th of January 2022 and had its most recent update 2nd of November that same year."
How many locations can participants access this clinical experiment?
"Currently, 8 medical centres are recruiting patients into this study. Huntersville, Boston and Newport Beach are some of the cities participating in the trial; additional sites can be found on the website. We suggest that you pick a centre close to your home to reduce any travel costs associated with enrolling in this study."
How many total participants are enrolled in this clinical experiment?
"The sponsor, Xilio Development, Inc., will be running the trial out of multiple sites including Carolina BioOncology Institute in Huntersville and Massachusetts General Hospital. To execute this study successfully, a total 189 participants that meet its inclusion criteria are required."
Share this study with friends
Copy Link
Messenger